The DOI matches its Crossref record; 236 of the 236 references it cites were found in a registry or an index.
Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review
Open accessAbstract
Glioblastoma (GBM) is the most common primary malignant brain tumor in adults and has an exceedingly low median overall survival of only 15 months. Current standard-of-care for GBM consists of gross total surgical resection followed by radiation with concurrent and adjuvant chemotherapy. Temozolomide (TMZ) is the first-choice chemotherapeutic agent in GBM; however, the development of resistance to TMZ often becomes the limiting factor in effective treatment. While O6-methylguanine-DNA methyltransferase repair activity and uniquely resistant populations of glioma stem cells are the most well-known contributors to TMZ resistance, many other molecular mechanisms have come to light in recent years. Key emerging mechanisms include the involvement of other DNA repair systems, aberrant signaling pathways, autophagy, epigenetic modifications, microRNAs, and extracellular vesicle production. This review aims to provide a comprehensive overview of the clinically relevant molecular mechanisms and their extensive interconnections to better inform efforts to combat TMZ resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Bhuvanalakshmi, G., Arfuso, F., Millward, M., Dharmarajan, A., & Warrier, S. R. (2015) · PLoS ONE · doi:10.1371/journal.pone.0127517 · Cited by 72
RetractedBartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W. K., Ohgaki, H., Wiestler, O. D., Kleihues, P., & Ellison, D. W. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1545-1 · Cited by 15,657
Ostrom, Q. T., Gittleman, H., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz-Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 11,994
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., & Rich, J. N. (2006) · Nature · doi:10.1038/nature05236 · Cited by 6,379
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919
Stupp, R., Taillibert, S., Kanner, A., Read, W., Steinberg, D. M., Lhermitte, B., Toms, S., Idbaih, A., Ahluwalia, M. S., Fink, K., et al. (2017) · JAMA · doi:10.1001/jama.2017.18718 · Cited by 2,644
Ostrom, Q. T., Cioffi, G., Gittleman, H., Patil, N., Waite, K., Kruchko, C., & Barnholtz-Sloan, J. S. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz150 · Cited by 2,585
Ostrom, Q. T., Cioffi, G., Waite, K., Kruchko, C., & Barnholtz-Sloan, J. S. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab200 · Cited by 2,529
A restricted cell population propagates glioblastoma growth after chemotherapy
Chen, J., Li, Y., Yu, T.-S., McKay, R. M., Burns, D. K., Kernie, S. G., & Parada, L. F. (2012) · Nature · doi:10.1038/nature11287 · Cited by 2,354
Erasers of Histone Acetylation: The Histone Deacetylase Enzymes
Seto, E., & Yoshida, M. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a018713 · Cited by 1,989
ER stress-induced cell death mechanisms
Sano, R., & Reed, J. C. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2013.06.028 · Cited by 1,988
IAP proteins: blocking the road to death's door
Salvesen, G. S., & Duckett, C. S. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm830 · Cited by 1,756
The many faces and functions of β‐catenin
Valenta, T., Hausmann, G., & Basler, K. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.150 · Cited by 1,598
Histone deacetylase inhibitors: molecular mechanisms of action
Xu, W. S., Parmigiani, R. B., & Marks, P. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210620 · Cited by 1,542
ULK1 induces autophagy by phosphorylating Beclin-1 and activating VPS34 lipid kinase
Russell, R. C., Tian, Y., Yuan, H., Park, H. W., Chang, Y.-Y., Kim, J., Kim, H., Neufeld, T. P., Dillin, A., & Guan, K.-L. (2013) · Nature Cell Biology · doi:10.1038/ncb2757 · Cited by 1,529
Gregoretti, I., Lee, Y.-M., & Goodson, H. V. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.02.006 · Cited by 1,456
Ostrom, Q. T., Price, M., Neff, C., Cioffi, G., Waite, K. A., Kruchko, C., & Barnholtz-Sloan, J. S. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad149 · Cited by 1,294
Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment
Sui, X., Chen, R., Wang, Z., Huang, Z., Kong, N., Zhang, M., Han, W., Lou, F., Yang, J., Zhang, Q., et al. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.350 · Cited by 1,204
Temozolomide resistance in glioblastoma multiforme
Lee, S. Y. (2016) · Genes & Diseases · doi:10.1016/j.gendis.2016.04.007 · Cited by 1,163
Akt, FoxO and regulation of apoptosis
Zhang, X., Tang, N., Hadden, T. J., & Rishi, A. K. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.03.010 · Cited by 1,103
The role of histone deacetylases (HDACs) in human cancer
Ropero, S., & Esteller, M. (2007) · Molecular Oncology · doi:10.1016/j.molonc.2007.01.001 · Cited by 997
Ignatova, T. N., Kukekov, V. G., Laywell, E. D., Suslov, O. N., Vrionis, F. D., & Steindler, D. A. (2002) · Glia · doi:10.1002/glia.10094 · Cited by 992
Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells
Kanzawa, T., Germano, I. M., Komata, T., Ito, H., Kondo, Y., & Kondo, S. (2004) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401359 · Cited by 986
A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles.
Paglin, S., Hollister, T. C., Delohery, T. M., Hackett, N., McMahill, M., Sphicas, E., Domingo, D., & Yahalom, J. (2001) · PubMed · Cited by 952
Long-term survival with glioblastoma multiforme
Krex, D., Klink, B., Hartmann, C., von Deimling, A., Pietsch, T., Simon, M., Sabel, M., Steinbach, J. P., Heese, O., Reifenberger, G., et al. (2007) · Brain · doi:10.1093/brain/awm204 · Cited by 887
Temozolomide: Mechanisms of Action, Repair and Resistance
Zhang, J., F.G. Stevens, M., & D. Bradshaw, T. (2012) · Current Molecular Pharmacology · doi:10.2174/1874467211205010102 · Cited by 885
Glioma Subclassifications and Their Clinical Significance
Chen, R., Smith-Cohn, M., Cohen, A. L., & Colman, H. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0519-x · Cited by 812
Kim, E., Kim, M., Woo, D.-H., Shin, Y., Shin, J., Chang, N., Oh, Y. T., Kim, H., Rheey, J., Nakano, I., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.04.008 · Cited by 806
MGMT promoter methylation in malignant gliomas: ready for personalized medicine?
Weller, M., Stupp, R., Reifenberger, G., Brandes, A. A., van den Bent, M. J., Wick, W., & Hegi, M. E. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.197 · Cited by 778
High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Stupp, R., Brada, M., van den Bent, M. J., Tonn, J.-C., & Pentheroudakis, G. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu050 · Cited by 772
Temozolomide and treatment of malignant glioma
Friedman, H. S., Kerby, T., & Calvert, H. (2000) · PubMed · doi:10.25405/ncl.34644405 · Cited by 731
Glioblastoma survival in the United States before and during the temozolomide era
Johnson, D. R., & O’Neill, B. P. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0749-4 · Cited by 720
Molecular targeted therapy of glioblastoma
Le Rhun, E., Preusser, M., Roth, P., Reardon, D. A., van den Bent, M., Wen, P., Reifenberger, G., & Weller, M. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.101896 · Cited by 688
Mechanisms and therapeutic implications of hypermutation in gliomas
Touat, M., Li, Y. Y., Boynton, A. N., Spurr, L. F., Iorgulescu, J. B., Bohrson, C. L., Cortes-Ciriano, I., Birzu, C., Geduldig, J. E., Pelton, K., et al. (2020) · Nature · doi:10.1038/s41586-020-2209-9 · Cited by 677
Survival in glioblastoma: a review on the impact of treatment modalities
Delgado-López, P. D., & Corrales-García, E. M. (2016) · Clinical and Translational Oncology · doi:10.1007/s12094-016-1497-x · Cited by 659
The molecular mechanisms of chemoresistance in cancers
Zheng, H.-C. (2017) · Oncotarget · doi:10.18632/oncotarget.19048 · Cited by 624
Chip-based analysis of exosomal mRNA mediating drug resistance in glioblastoma
Shao, H., Chung, J., Lee, K., Balaj, L., Min, C., Carter, B. S., Hochberg, F. H., Breakefield, X. O., Lee, H., & Weissleder, R. (2015) · Nature Communications · doi:10.1038/ncomms7999 · Cited by 612
FOXOs, cancer and regulation of apoptosis
Fu, Z., & Tindall, D. J. (2008) · Oncogene · doi:10.1038/onc.2008.24 · Cited by 584
Zhang, N., Wei, P., Gong, A., Chiu, W.-T., Lee, H.-T., Colman, H., Huang, H., Xue, J., Liu, M., Wang, Y., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.08.016 · Cited by 584
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
KOMOTAR, R. J., WILSON, D. A., & CONNOLLY, E. S. (2005) · Neurosurgery · doi:10.1093/neurosurgery/57.1.n7a · Cited by 570
Herrlinger, U., Tzaridis, T., Mack, F., Steinbach, J. P., Schlegel, U., Sabel, M., Hau, P., Kortmann, R.-D., Krex, D., Grauer, O., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)31791-4 · Cited by 568
Akt‐mediated regulation of NFκB and the essentialness of NFκB for the oncogenicity of PI3K and Akt
Bai, D., Ueno, L., & Vogt, P. K. (2009) · International Journal of Cancer · doi:10.1002/ijc.24748 · Cited by 529
Rosenfeld, M. R., Ye, X., Supko, J. G., Desideri, S., Grossman, S. A., Brem, S., Mikkelson, T., Wang, D., Chang, Y. C., Hu, J., et al. (2014) · Autophagy · doi:10.4161/auto.28984 · Cited by 515
The Roles of Therapy-Induced Autophagy and Necrosis in Cancer Treatment
Amaravadi, R. K., & Thompson, C. B. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1595 · Cited by 465
MGMT Gene Silencing and Benefit From Temozolomide in Glioblastoma
Verma, A. (2006) · Yearbook of Neurology and Neurosurgery · doi:10.1016/s0513-5117(08)70328-4 · Cited by 452
Rivera, A. L., Pelloski, C. E., Gilbert, M. R., Colman, H., De La Cruz, C., Sulman, E. P., Bekele, B. N., & Aldape, K. D. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop020 · Cited by 434
Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy
Carew, J. S., Giles, F. J., & Nawrocki, S. T. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.03.037 · Cited by 421
Kim, H., Zheng, S., Amini, S. S., Virk, S. M., Mikkelsen, T., Brat, D. J., Grimsby, J., Sougnez, C., Muller, F., Hu, J., et al. (2015) · Genome Research · doi:10.1101/gr.180612.114 · Cited by 411
Fate mapping of human glioblastoma reveals an invariant stem cell hierarchy
Lan, X., Jörg, D. J., Cavalli, F. M. G., Richards, L. M., Nguyen, L. V., Vanner, R. J., Guilhamon, P., Lee, L., Kushida, M. M., Pellacani, D., et al. (2017) · Nature · doi:10.1038/nature23666 · Cited by 405
Autophagy and cancer stem cells: molecular mechanisms and therapeutic applications
Nazio, F., Bordi, M., Cianfanelli, V., Locatelli, F., & Cecconi, F. (2019) · Cell Death & Differentiation · doi:10.1038/s41418-019-0292-y · Cited by 388
Cancer metabolism: current perspectives and future directions
Muñoz-Pinedo, C., El Mjiyad, N., & Ricci, J.-E. (2012) · Cell Death & Disease · doi:10.1038/cddis.2011.123 · Cited by 385
Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation
Morris, L. G. T., Kaufman, A. M., Gong, Y., Ramaswami, D., Walsh, L. A., Turcan, Ş., Eng, S., Kannan, K., Zou, Y., Peng, L., et al. (2013) · Nature Genetics · doi:10.1038/ng.2538 · Cited by 366
Targeting cellular pathways in glioblastoma multiforme
Pearson, J. R. D., & Regad, T. (2017) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2017.40 · Cited by 344
Shi, L., Chen, J., Yang, J., Pan, T., Zhang, S., & Wang, Z. (2010) · Brain Research · doi:10.1016/j.brainres.2010.07.009 · Cited by 343
Akers, J. C., Ramakrishnan, V., Kim, R., Skog, J., Nakano, I., Pingle, S., Kalinina, J., Hua, W., Kesari, S., Mao, Y., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078115 · Cited by 337
Hitosugi, T., Fan, J., Chung, T.-W., Lythgoe, K., Wang, X., Xie, J., Ge, Q., Gu, T.-L., Polakiewicz, R. D., Roesel, J. L., et al. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.10.015 · Cited by 334
Plathow, C., & Weber, W. A. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.045930 · Cited by 328
Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma
JIAPAER, S., FURUTA, T., TANAKA, S., KITABAYASHI, T., & NAKADA, M. (2018) · Neurologia medico-chirurgica · doi:10.2176/nmc.ra.2018-0141 · Cited by 324
A Combined Preclinical Therapy of Cannabinoids and Temozolomide against Glioma
Torres, S., Lorente, M., Rodríguez-Fornés, F., Hernández-Tiedra, S., Salazar, M., García-Taboada, E., Barcia, J., Guzmán, M., & Velasco, G. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0688 · Cited by 301
Targeting autophagy to sensitive glioma to temozolomide treatment
Yan, Y., Xu, Z., Dai, S., Qian, L., Sun, L., & Gong, Z. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0303-5 · Cited by 299
Hombach-Klonisch, S., Mehrpour, M., Shojaei, S., Harlos, C., Pitz, M., Hamai, A., Siemianowicz, K., Likus, W., Wiechec, E., Toyota, B. D., et al. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.10.017 · Cited by 292
Dynamic regulation of macroautophagy by distinctive ubiquitin-like proteins
Klionsky, D. J., & Schulman, B. A. (2014) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2787 · Cited by 278
Extracellular vesicles and anti-cancer drug resistance
Namee, N. M., & O'Driscoll, L. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.07.003 · Cited by 274
Knizhnik, A. V., Roos, W. P., Nikolova, T., Quiros, S., Tomaszowski, K.-H., Christmann, M., & Kaina, B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055665 · Cited by 273
PLAGL2 Regulates Wnt Signaling to Impede Differentiation in Neural Stem Cells and Gliomas
Zheng, H., Ying, H., Wiedemeyer, R., Yan, H., Quayle, S. N., Ivanova, E. V., Paik, J.-H., Zhang, H., Xiao, Y., Perry, S. R., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.020 · Cited by 271
Zhang, Z., Yin, J., Lu, C., Wei, Y., Zeng, A., & You, Y. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1139-6 · Cited by 265
Targeting adaptive glioblastoma: an overview of proliferation and invasion
Xie, Q., Mittal, S., & Berens, M. E. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou147 · Cited by 262
Self-citationLo, H.-W., Cao, X., Zhu, H., & Ali-Osman, F. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4923 · Cited by 253
Franovic, A., Gunaratnam, L., Smith, K., Robert, I., Patten, D., & Lee, S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702387104 · Cited by 250
Segerman, A., Niklasson, M., Haglund, C., Bergström, T., Jarvius, M., Xie, Y., Westermark, A., Sönmez, D., Hermansson, A., Kastemar, M., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.11.056 · Cited by 249
Glioblastoma: exosome and microRNA as novel diagnosis biomarkers
Saadatpour, L., Fadaee, E., Fadaei, S., Nassiri Mansour, R., Mohammadi, M., Mousavi, S. M., Goodarzi, M., Verdi, J., & Mirzaei, H. (2016) · Cancer Gene Therapy · doi:10.1038/cgt.2016.48 · Cited by 244
Trivedi, R. N., Almeida, K. H., Fornsaglio, J. L., Schamus, S., & Sobol, R. W. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0715 · Cited by 242
Targeting EGFR for Treatment of Glioblastoma: Molecular Basis to Overcome Resistance
E. Taylor, T., B. Furnari, F., & K. Cavenee, W. (2012) · Current Cancer Drug Targets · doi:10.2174/156800912799277557 · Cited by 240
Treatment of Glioblastoma (GBM) with the Addition of Tumor-Treating Fields (TTF): A Review
Fabian, D., Guillermo Prieto Eibl, M. D. P., Alnahhas, I., Sebastian, N., Giglio, P., Puduvalli, V., Gonzalez, J., & Palmer, J. D. (2019) · Cancers · doi:10.3390/cancers11020174 · Cited by 240
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
Uhm, J. (2009) · Yearbook of Neurology and Neurosurgery · doi:10.1016/s0513-5117(09)79089-1 · Cited by 239
Messaoudi, K., Clavreul, A., & Lagarce, F. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.02.011 · Cited by 238
Kahlert, U. D., Maciaczyk, D., Doostkam, S., Orr, B. A., Simons, B., Bogiel, T., Reithmeier, T., Prinz, M., Schubert, J., Niedermann, G., et al. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.05.024 · Cited by 231
Wickström, M., Dyberg, C., Milosevic, J., Einvik, C., Calero, R., Sveinbjörnsson, B., Sandén, E., Darabi, A., Siesjö, P., Kool, M., et al. (2015) · Nature Communications · doi:10.1038/ncomms9904 · Cited by 229
Ujifuku, K., Mitsutake, N., Takakura, S., Matsuse, M., Saenko, V., Suzuki, K., Hayashi, K., Matsuo, T., Kamada, K., Nagata, I., et al. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.04.013 · Cited by 228
Lin, C.-J., Lee, C.-C., Shih, Y.-L., Lin, T.-Y., Wang, S.-H., Lin, Y.-F., & Shih, C.-M. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.10.487 · Cited by 225
Zhou, J., Schmid, T., Frank, R., & Brüne, B. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310164200 · Cited by 225
EGFR as a Target for Glioblastoma Treatment: An Unfulfilled Promise
Westphal, M., Maire, C. L., & Lamszus, K. (2017) · CNS Drugs · doi:10.1007/s40263-017-0456-6 · Cited by 221
Selective targeting of radiation-resistant tumor-initiating cells
Zhang, M., Atkinson, R. L., & Rosen, J. M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910179107 · Cited by 216
Ren, Y., Zhou, X., Mei, M., Yuan, X.-B., Han, L., Wang, G.-X., Jia, Z.-F., Xu, P., Pu, P.-Y., & Kang, C.-S. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-27 · Cited by 216
MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme
Li, Y., Li, W., Yang, Y., Lu, Y., He, C., Hu, G., Liu, H., Chen, J., He, J., & Yu, H. (2009) · Brain Research · doi:10.1016/j.brainres.2009.06.053 · Cited by 213
Garg, M. (2013) · World Journal of Stem Cells · doi:10.4252/wjsc.v5.i4.188 · Cited by 209
MicroRNAs in glioblastoma multiforme pathogenesis and therapeutics
Shea, A., Harish, V., Afzal, Z., Chijioke, J., Kedir, H., Dusmatova, S., Roy, A., Ramalinga, M., Harris, B., Blancato, J., et al. (2016) · Cancer Medicine · doi:10.1002/cam4.775 · Cited by 209
STAT3 Inhibition Overcomes Temozolomide Resistance in Glioblastoma by Downregulating MGMT Expression
Kohsaka, S., Wang, L., Yachi, K., Mahabir, R., Narita, T., Itoh, T., Tanino, M., Kimura, T., Nishihara, H., & Tanaka, S. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0801 · Cited by 199
Perazzoli, G., Prados, J., Ortiz, R., Caba, O., Cabeza, L., Berdasco, M., Gónzalez, B., & Melguizo, C. (2015) · PLOS ONE · doi:10.1371/journal.pone.0140131 · Cited by 198
Zanotto-Filho, A., Braganhol, E., Klafke, K., Figueiró, F., Terra, S. R., Paludo, F. J., Morrone, M., Bristot, I. J., Battastini, A. M., Forcelini, C. M., et al. (2015) · Cancer Letters · doi:10.1016/j.canlet.2014.12.044 · Cited by 196
miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression
Zhang, W., Zhang, J., Hoadley, K., Kushwaha, D., Ramakrishnan, V., Li, S., Kang, C., You, Y., Jiang, C., Song, S. W., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos089 · Cited by 196
Ashby, L. S., Smith, K. A., & Stea, B. (2016) · World Journal of Surgical Oncology · doi:10.1186/s12957-016-0975-5 · Cited by 192
Zeng, A., Wei, Z., Yan, W., Yin, J., Huang, X., Zhou, X., Li, R., Shen, F., Wu, W., Wang, X., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.08.004 · Cited by 192
DNA repair mechanisms and their clinical impact in glioblastoma
Erasimus, H., Gobin, M., Niclou, S., & Van Dyck, E. (2016) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2016.05.005 · Cited by 188
Chloroquine enhances temozolomide cytotoxicity in malignant gliomas by blocking autophagy
Golden, E. B., Cho, H.-Y., Jahanian, A., Hofman, F. M., Louie, S. G., Schönthal, A. H., & Chen, T. C. (2014) · Neurosurgical Focus · doi:10.3171/2014.9.focus14504 · Cited by 179
Würth, R., Bajetto, A., Harrison, J. K., Barbieri, F., & Florio, T. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00144 · Cited by 172
Comincini, S., Allavena, G., Palumbo, S., Morini, M., Durando, F., Angeletti, F., Pirtoli, L., & Miracco, C. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.24597 · Cited by 163
IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry
Yang, P., Zhang, W., Wang, Y., Peng, X., Chen, B., Qiu, X., Li, G., Li, S., Wu, C., Yao, K., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5683 · Cited by 162
Joensuu, H., Puputti, M., Sihto, H., Tynninen, O., & Nupponen, N. N. (2005) · The Journal of Pathology · doi:10.1002/path.1823 · Cited by 158
The emergent role of exosomes in glioma
Gourlay, J., Morokoff, A. P., Luwor, R. B., Zhu, H., Kaye, A. H., & Stylli, S. S. (2016) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2016.09.021 · Cited by 153
Chloroquine activates the p53 pathway and induces apoptosis in human glioma cells
Kim, E. L., Wuestenberg, R., Rübsam, A., Schmitz-Salue, C., Warnecke, G., Bucker, E.-M., Pettkus, N., Speidel, D., Rohde, V., Schulz‐Schaeffer, W., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop046 · Cited by 148
Garnier, D., Meehan, B., Kislinger, T., Daniel, P. M., Sinha, A., Abdulkarim, B., Nakano, I., & Rak, J. W. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox142 · Cited by 147
The Challenges and the Promise of Molecular Targeted Therapy in Malignant Gliomas
Wang, H., Xu, T., Jiang, Y., Xu, H., Yan, Y., Fu, D., & Chen, J. (2015) · Neoplasia · doi:10.1016/j.neo.2015.02.002 · Cited by 145
Huang, M., Zhang, D., Wu, J. Y., Xing, K., Yeo, E., Li, C., Zhang, L., Holland, E. C., Yao, L., Qin, L., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay7522 · Cited by 143
MicroRNA involvement in glioblastoma pathogenesis
Nováková, J., Slabý, O., Vyzula, R., & Michálek, J. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.06.034 · Cited by 141
Chu, C.-W., Ko, H.-J., Chou, C., Cheng, T.-S., Cheng, H.-W., Liang, Y.-H., Lai, Y.-L., Lin, C.-Y., Wang, C., Loh, J., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030473 · Cited by 140
Ma, K., Ivanov, V. N., Dong, J., & Ronai, Z. A. (2003) · Oncogene · doi:10.1038/sj.onc.1206598 · Cited by 135
Glioblastoma vs temozolomide: can the red queen race be won?
Arora, A., & Somasundaram, K. (2019) · Cancer Biology & Therapy · doi:10.1080/15384047.2019.1599662 · Cited by 135
Kamino, M., Kishida, M., Kibe, T., Ikoma, K., Iijima, M., Hirano, H., Tokudome, M., Chen, L., Koriyama, C., Yamada, K., et al. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01815.x · Cited by 132
Velpula, K. K., Bhasin, A., Asuthkar, S., & Tsung, A. J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1868 · Cited by 132
DNA Repair Capacity in Multiple Pathways Predicts Chemoresistance in Glioblastoma Multiforme
Nagel, Z. D., Kitange, G. J., Gupta, S. K., Joughin, B. A., Chaim, I. A., Mazzucato, P., Lauffenburger, D. A., Sarkaria, J. N., & Samson, L. D. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1151 · Cited by 131
Zeng, A.-L., Yan, W., Liu, Y.-W., Wang, Z., Hu, Q., Nie, E., Xin Min, Z. H. O. U., Li, R., Wang, X.-F., Jiang, T., et al. (2017) · Oncogene · doi:10.1038/onc.2017.134 · Cited by 129
Xu, H., Wei, L., Zhang, Y., Liu, L., Luo, X., Zeng, Y., Wu, H., Lan, Q., & Chu, Z. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-330 · Cited by 127
Tang, J.-B., Svilar, D., Trivedi, R. N., Wang, X., Goellner, E. M., Moore, B., Hamilton, R. L., Banze, L. A., Brown, A. R., & Sobol, R. W. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor011 · Cited by 127
Yoshimoto, K., Mizoguchi, M., Hata, N., Murata, H., Hatae, R., Amano, T., Nakamizo, A., & Sasaki, T. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00186 · Cited by 126
Shi, L. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1179 · Cited by 122
Lin, C., Lee, C.-C., Shih, Y., Lin, C., Wang, S.-H., Chen, T.-H., & Shih, C.-M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038706 · Cited by 121
Reprogramming cell death: BCL2 family inhibition in hematological malignancies
Scarfò, L., & Ghia, P. (2013) · Immunology Letters · doi:10.1016/j.imlet.2013.09.015 · Cited by 119
The NFκB pathway: a therapeutic target in glioblastoma
Nogueira, L., Ruiz-Ontañón, P., Vázquez-Barquero, A., Morís, F., & Fernández-Luna, J. L. (2011) · Oncotarget · doi:10.18632/oncotarget.322 · Cited by 115
Vps34 Kinase Domain Dynamics Regulate the Autophagic PI 3-Kinase Complex
Stjepanović, G., Baskaran, S., Lin, M. G., & Hurley, J. H. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.07.003 · Cited by 115
Control of glioblastoma tumorigenesis by feed-forward cytokine signaling
Jahani‐Asl, A., Yin, H., Soleimani, V. D., Haque, T., Luchman, H. A., Chang, N. C., Sincennes, M., Puram, S. V., Scott, A. M., Lorimer, I. A. J., et al. (2016) · Nature Neuroscience · doi:10.1038/nn.4295 · Cited by 114
Liao, H., Bai, Y., Qiu, S., Zheng, L., Huang, L., Liu, T., Wang, X., Liu, Y., Xu, N., Yan, X., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3563 · Cited by 113
Sandberg, C. J., Altschuler, G. M., Jeong, J., Kierulf-Vieira, K. S., Stangeland, B., Murrell, W. G., Grasmo-Wendler, U.-H., Myklebost, O., Helseth, E., Vik-Mo, E. O., et al. (2013) · Experimental Cell Research · doi:10.1016/j.yexcr.2013.06.004 · Cited by 112
Sunayama, J., Sato, A., Matsuda, K., Tachibana, K., Watanabe, E., Seino, S., Suzuki, K., Narita, Y., Shibui, S., Sakurada, K., et al. (2011) · Stem Cells · doi:10.1002/stem.696 · Cited by 110
Histone deacetylase inhibitors in glioblastoma: pre-clinical and clinical experience
Bezecny, P. (2014) · Medical Oncology · doi:10.1007/s12032-014-0985-5 · Cited by 109
Woodhouse, B. C., Dianova, I. I., Parsons, J. L., & Dianov, G. L. (2008) · DNA repair · doi:10.1016/j.dnarep.2008.03.017 · Cited by 108
Advances in epigenetic glioblastoma therapy
Lee, D. H., Ryu, H.-W., Won, H.-R., & Kwon, S. H. (2017) · Oncotarget · doi:10.18632/oncotarget.14612 · Cited by 108
Genetic, Epigenetic, and Immunologic Profiling of MMR-Deficient Relapsed Glioblastoma
Indraccolo, S., Lombardi, G., Fassan, M., Pasqualini, L., Giunco, S., Marcato, R., Gasparini, A., Candiotto, C., Nalio, S., Fiduccia, P., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1892 · Cited by 108
miR-221/222 Target the DNA Methyltransferase MGMT in Glioma Cells
Quintavalle, C., Mangani, D., Roscigno, G., Romano, G., Díaz‐Lagares, Á., Iaboni, M., Donnarumma, E., Fiore, D., Marinis, P. D., Soini, Y., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074466 · Cited by 105
The role of miR-130a in cancer
Zhang, H.-D., Jiang, L., Sun, D., Li, J., & Ji, Z. (2017) · Breast Cancer · doi:10.1007/s12282-017-0776-x · Cited by 104
β‐catenin as a potential key target for tumor suppression
Fu, Y., Zheng, S., An, N., Athanasopoulos, T., Popplewell, L. J., Liang, A., Li, K., Hu, C., & Zhu, Y. (2011) · International Journal of Cancer · doi:10.1002/ijc.26102 · Cited by 102
Kore, R. A., Edmondson, J. L., Jenkins, S. V., Jamshidi‐Parsian, A., Dings, R. P. M., Reyna, N. S., & Griffin, R. J. (2018) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2018.03.008 · Cited by 102
Lu, Y., Zhou, J., Xu, C., Lin, H., Xiao, J., Wang, Z., & Yang, B. (2008) · Cellular Physiology and Biochemistry · doi:10.1159/000129389 · Cited by 100
Parsons, J. L., Dianova, I. I., Allinson, S. L., & Dianov, G. L. (2005) · FEBS Journal · doi:10.1111/j.1742-4658.2005.04628.x · Cited by 99
Epigenetic regulation of the miR142-3p/interleukin-6 circuit in glioblastoma.
Chiou, G.-Y., Chien, C.-S., Wang, M.-L., Chen, M.-T., Yang, Y.-P., Yu, Y.-L., Chien, Y., Chang, Y.-C., Shen, C.-C., Chio, C., et al. (2013) · Molecules and Cells · doi:10.1016/j.molcel.2013.11.009 · Cited by 99
Filippi‐Chiela, E. C., Silva, M. M. B. E., Thomé, M. P. M., & Lenz, G. (2015) · Autophagy · doi:10.1080/15548627.2015.1009795 · Cited by 98
Lan, F., Pan‐Hammarström, Q., Yu, H., & Yue, X. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13174 · Cited by 98
Huang, T., Alvarez, A. A., Pangeni, R. P., Horbinski, C., Lu, S., Kim, S.-H., James, C. D., Raizer, J. J., Kessler, J. A., Brenann, C., et al. (2016) · Nature Communications · doi:10.1038/ncomms12885 · Cited by 98
miR-129-5p targets Wnt5a to block PKC/ERK/NF-κB and JNK pathways in glioblastoma
Zeng, A., Yin, J., Li, Y., Li, R., Wang, Z., Zhou, X., Jin, X., Shen, F., Yan, W., & You, Y. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0343-1 · Cited by 98
Jiang, C. (2011) · Oncology Reports · doi:10.3892/or.2011.1535 · Cited by 96
Wong, T., Zhang, X., Zhuang, J. T.-F., Chan, H.-L., Li, C.-H., & Leung, G. (2012) · PubMed · Cited by 94
STAT3 Mediates Resistance to MEK Inhibitor through MicroRNA miR-17
Dai, B., Meng, J., Peyton, M., Girard, L., Bornmann, W. G., Ji, L., Minna, J. D., Fang, B., & Roth, J. A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3647 · Cited by 94
Kreth, S., Limbeck, E., Hinske, L. C., Schütz, S. V., Thon, N., Hoefig, K. P., Egensperger, R., & Kreth, F. W. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1081-1 · Cited by 94
Extracellular Vesicles in Brain Tumor Progression
D’Asti, E., Chennakrishnaiah, S., Lee, T. H., & Rak, J. W. (2016) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-015-0296-1 · Cited by 91
Understanding Glioblastoma Biomarkers: Knocking a Mountain with a Hammer
Mesrati, M. H., Behrooz, A. B., Abuhamad, A. Y., & Syahir, A. (2020) · Cells · doi:10.3390/cells9051236 · Cited by 91
Haemmig, S., Baumgartner, U., Glück, A., Zbinden, S., Tschan, M. P., Каппелер, А., Mariani, L., Vajtai, I., & Vassella, E. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.245 · Cited by 90
Blockage of a miR-21/EGFR regulatory feedback loop augments anti-EGFR therapy in glioblastomas
Zhang, K.-L., Han, L., Chen, L., Shi, Z., Yang, M., Ren, Y., Chen, L., Zhang, J., Pu, P., & Kang, C. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.08.043 · Cited by 90
Qian, Z., Ren, L., Wu, D., Yang, X., Zhou, Z., Nie, Q., Jiang, G., Xue, S., Weng, W., Qiu, Y., et al. (2017) · International Journal of Cancer · doi:10.1002/ijc.30690 · Cited by 89
Thioridazine inhibits autophagy and sensitizes glioblastoma cells to temozolomide
Johannessen, T.-C. A., Hasan‐Olive, M. M., Zhu, H., Denisova, O. V., Grudic, A., Latif, A., Saed, H. S., Varughese, J. K., Røsland, G. V., Yang, N., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31912 · Cited by 89
STAT Signaling in Glioma Cells
Swiatek-Machado, K., & Kaminska, B. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-30651-9_10 · Cited by 86
Liu, J.-R., Yu, C., Hung, P.-Y., Hsin, L., & Chern, J. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.03.023 · Cited by 84
Costa, P. M., Cardoso, A. L., Nóbrega, C., Pereira de Almeida, L. F., Bruce, J. N., Canoll, P., & Pedroso de Lima, M. C. (2013) · Human Molecular Genetics · doi:10.1093/hmg/dds496 · Cited by 80
Agnihotri, S., Burrell, K. E., Buczkowicz, P., Remke, M., Golbourn, B. J., Chornenkyy, Y., Gajadhar, A. S., Fernandez, N. A., Clarke, I. D., Barszczyk, M., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0157 · Cited by 80
Sharfe, N., Dadi, H., & Roifman, C. M. (1995) · Blood · doi:10.1182/blood.v86.6.2077.bloodjournal8662077 · Cited by 80
Tomar, V. S., Patil, V. S., & Somasundaram, K. (2019) · Cell Biology and Toxicology · doi:10.1007/s10565-019-09502-7 · Cited by 79
Feldheim, J., Kessler, A. F., Monoranu, C. M., Ernestus, R., Löhr, M., & Hagemann, C. (2019) · Cancers · doi:10.3390/cancers11121837 · Cited by 77
A genome-wide miRNA screen revealed miR-603 as a MGMT-regulating miRNA in glioblastomas
Kushwaha, D. S., Ramakrishnan, V., Ng, K., Steed, T., Nguyen, T. P., Futalan, D., Akers, J. C., Sarkaria, J. N., Jiang, T., Chowdhury, D., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1974 · Cited by 75
Radiotherapy and concomitant temozolomide may improve survival of elderly patients with glioblastoma
Barker, C. A., Chang, M., Chou, J. F., Zhang, Z., Beal, K. P., Gutin, P. H., & IWAMOTO, F. M. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-0906-4 · Cited by 75
Zhang, S., Wan, Y., Pan, T., Gu, X., Qian, C., Sun, G., Sun, L., Xiang, Y., Wang, Z., & Shi, L. (2012) · Journal of Molecular Neuroscience · doi:10.1007/s12031-012-9759-8 · Cited by 74
STAT Signaling in Glioma Cells
Swiatek-Machado, K., & Kaminska, B. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-94-007-4719-7_10 · Cited by 74
Role of micro-RNA (miRNA) in pathogenesis of glioblastoma.
Luo, J., WANG, X.-G., Yang, Y., & Mao, Q. (2015) · PubMed · Cited by 74
VEGF Manipulation in Glioblastoma.
Weathers, S.-P. S., & de Groot, J. (2015) · PubMed · Cited by 74
Augmented HR Repair Mediates Acquired Temozolomide Resistance in Glioblastoma
del Alcazar, C. R. G., Todorova, P. K., Habib, A. A., Mukherjee, B., & Burma, S. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0125 · Cited by 73
Riganti, C., Salaroglio, I. C., Caldera, V., Campia, I., Kopecka, J., Mellai, M., Annovazzi, L., Bosìa, A., Ghigo, D., & Schiffer, D. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not104 · Cited by 72
Extracellular Vesicles in Glioma: From Diagnosis to Therapy
Basu, B., & Ghosh, M. K. (2019) · BioEssays · doi:10.1002/bies.201800245 · Cited by 72
Ulasov, I. V., Sonabend, A. M., Nandi, S., Khramtsov, A., Han, Y., & Lesniak, M. S. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604969 · Cited by 71
Repair mechanisms help glioblastoma resist treatment
Atkins, R. J., Ng, W., Stylli, S. S., Hovens, C. M., & Kaye, A. H. (2014) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2014.09.003 · Cited by 69
Mittal, S., Klinger, N. V., Michelhaugh, S. K., Barger, G. R., Pannullo, S. C., & Juhász, C. (2017) · Journal of neurosurgery · doi:10.3171/2016.9.jns16452 · Cited by 68
Self-citationDeegan, S., Saveljeva, S., Logue, S. E., Pakos‐Zebrucka, K., Gupta, S., Vandenabeele, P., Bertrand, M. J. M., & Samali, A. (2014) · Autophagy · doi:10.4161/15548627.2014.981790 · Cited by 67
Brognara, E., Fabbri, E., Montagner, G., Gasparello, J., Manicardi, A., Corradini, R., Bianchi, N., Finotti, A., Breveglieri, G., Borgatti, M., et al. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3308 · Cited by 67
Li, C., Liu, Y., Liu, H., Zhang, W., Shen, C., Cho, K., Chen, X., Peng, F., Bi, Y., Hou, X., et al. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373952 · Cited by 66
Gerstner, E. R., Emblem, K. E., Chang, K., Vakulenko‐Lagun, B., Yen, Y., Beers, A. L., Dietrich, J., Plotkin, S. R., Catana, C., Hooker, J. M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1739 · Cited by 66
She, X., Yu, Z., Cui, Y., Lei, Q., Wang, Z., Xu, G., Xiang, J., Wu, M., & Li, G. (2014) · Oncology Reports · doi:10.3892/or.2014.3318 · Cited by 65
Struve, N., Binder, Z. A., Stead, L. F., Brend, T., Bagley, S. J., Faulkner, C., Ott, L. F., Müller-Goebel, J., Weik, A.-S., Hoffer, K., et al. (2020) · Oncogene · doi:10.1038/s41388-020-1208-5 · Cited by 65
Ye, F., Zhang, Y., Liu, Y., Yamada, K., Tso, J. L., Menjivar, J. C., Tian, J. Y., Yong, W. H., Schaue, D., Mischel, P. S., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080397 · Cited by 64
Wen, Z., Zeng, W., Chen, Y., He, L., Wang, J., Cheng, Q., Yu, J., Zhou, H., Liu, Z.-Z., Xiao, J., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1287-8 · Cited by 64
Genetic Evolution of Glioblastoma Stem-Like Cells From Primary to Recurrent Tumor
Orzan, F., Bacco, F. D., Crisafulli, G., Pellegatta, S., Mussolin, B., Siravegna, G., D’Ambrosio, A., Comoglio, P. M., Finocchiaro, G., & Boccaccio, C. (2017) · Stem Cells · doi:10.1002/stem.2703 · Cited by 63
Inhibition of histone deacetylases sensitizes glioblastoma cells to lomustine
Staberg, M., Michaelsen, S. R., Rasmussen, R. D., Villingshøj, M., Poulsen, H. S., & Hamerlik, P. (2017) · Cellular Oncology · doi:10.1007/s13402-016-0301-9 · Cited by 62
The strategy for enhancing temozolomide against malignant glioma
Nakada, M., Furuta, T., Hayashi, Y., Minamoto, T., & Hamada, J. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00098 · Cited by 62
Clinical implications of microRNAs in human glioblastoma
Mizoguchi, M., Guan, Y., Yoshimoto, K., Hata, N., Amano, T., Nakamizo, A., & Sasaki, T. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00019 · Cited by 62
Jy, C., Lo, W.-L., Ko, C.-Y., Chou, S.-Y., Chen, R.-M., Chang, K.-Y., Hung, J.-J., Su, W., Chang, W.-C., & Hsu, T.-I. (2017) · Oncogenesis · doi:10.1038/oncsis.2017.31 · Cited by 62
Li, Z., Li, Q.-Z., Chen, L., Chen, B.-D., Wang, B., Zhang, X., & Li, W.-P. (2016) · Neurochemical Research · doi:10.1007/s11064-016-2043-5 · Cited by 61
Zhou, J., Liang, Y., Ouyang, Q., Xu, L., Cui, H., & Xu, M. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.08.027 · Cited by 59
The Changes in MGMT Promoter Methylation Status in Initial and Recurrent Glioblastomas
Park, C., Kim, J., Kim, J. Y., Song, S. W., Kim, J. W., Choi, S. H., Kim, T. M., Lee, S., Kim, I. H., & Park, S. (2012) · Translational Oncology · doi:10.1593/tlo.12253 · Cited by 59
He, Y., Su, J., Lan, B., Gao, Y., & Zhao, J. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s194770 · Cited by 57
Effect of temozolomide on the U-118 glioma cell line
do Carmo, A., Carvalheiro, H., Crespo, I., Nunes‐Correia, I., & Lopes, M. C. (2011) · Oncology Letters · doi:10.3892/ol.2011.406 · Cited by 56
Caja, L., Tzavlaki, K., Dadras, M. S., Tan, E., Hatem, G., Maturi, N. P., Morén, A., Wik, L., Watanabe, Y., Savary, K., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0136-0 · Cited by 55
Therapeutic control and resistance of the EGFR-driven signaling network in glioblastoma
Azuaje, F. J., Tiemann, K., & Niclou, S. P. (2015) · Cell Communication and Signaling · doi:10.1186/s12964-015-0098-6 · Cited by 53
Understanding and Targeting Alkylator Resistance in Glioblastoma
Wick, W., & Platten, M. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0918 · Cited by 51
Kinzel, A., Ambrogi, M., Varshaver, M., & Kirson, E. D. (2019) · Clinical Medicine Insights Oncology · doi:10.1177/1179554918825449 · Cited by 51
MicroRNA‐155‐3p promotes glioma progression and temozolomide resistance by targeting Six1
Chen, G., Chen, Z., & Zhao, H. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15192 · Cited by 50
Skoda, J., Hermanová, M., Loja, T., Němec, P., Neradil, J., Karásek, P., & Veselská, R. (2016) · PLoS ONE · doi:10.1371/journal.pone.0159255 · Cited by 47
Kang, C. (2011) · Oncology Reports · doi:10.3892/or.2011.1396 · Cited by 45
Chen, H., Li, X., Li, W., & Zheng, H. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0435-y · Cited by 45
Li, S., Chen, X., Mao, L., Zahid, K. R., Wen, J., Zhang, L., Zhang, M., Duan, J., Duan, J., Yin, X., et al. (2018) · Brain Research · doi:10.1016/j.brainres.2018.05.023 · Cited by 45
Lu, C., Cui, C., Liu, B., Zou, S., Song, H., Tian, H., Zhao, J., & Li, Y. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2017.07.057 · Cited by 44
Cited by
Tomar, M. S., Kumar, A., Srivastava, C., & Shrivastava, A. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188616 · Cited by 325
Glioblastoma at the crossroads: current understanding and future therapeutic horizons
Singh, S., Dey, D., Barik, D., Mohapatra, I., Kim, S., Sharma, M., Prasad, S., Wang, P., Singh, A., & Singh, G. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02299-4 · Cited by 287
Glioblastoma Therapy: Past, Present and Future
Obrador, E., Moreno-Murciano, P., Oriol-Caballo, M., López-Blanch, R., Pineda, B., Gutiérrez-Arroyo, J., Loras, A., Gonzalez-Bonet, L., Martinez-Cadenas, C., Estrela, J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052529 · Cited by 271
Metadata
- Authors
- Singh, N., Miner, A., Hennis, L., & Mittal, S.
- Venue
- Cancer Drug Resistance
- Publisher
- OAE Publishing Inc.
- Published
- 2020
- Volume
- 4
- Pages
- 17-43
- ISSN
- 2578-532X (ISSN-L)
- OpenAlex
- W3109004754
- Cited by
- 398
- References
- 236
- FWCI
- 16.28
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.